Lone Peak Global Investors LLC Buys 120,352 Shares of Solventum Corporation $SOLV

Lone Peak Global Investors LLC lifted its position in Solventum Corporation (NYSE:SOLV) by 38.5% during the 2nd quarter, Holdings Channel.com reports. The fund owned 433,128 shares of the company’s stock after acquiring an additional 120,352 shares during the period. Solventum accounts for 4.6% of Lone Peak Global Investors LLC’s investment portfolio, making the stock its 3rd biggest holding. Lone Peak Global Investors LLC’s holdings in Solventum were worth $33,416,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. United Services Automobile Association purchased a new position in shares of Solventum in the first quarter worth about $239,000. Woodline Partners LP raised its position in Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after buying an additional 3,377 shares during the last quarter. Intech Investment Management LLC lifted its stake in Solventum by 167.0% during the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after acquiring an additional 10,425 shares during the period. First Trust Advisors LP boosted its holdings in shares of Solventum by 5.8% in the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after acquiring an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Solventum in the 2nd quarter valued at $766,000.

Solventum Stock Performance

NYSE SOLV opened at $90.86 on Wednesday. The stock has a market capitalization of $15.47 billion, a price-to-earnings ratio of 11.11, a PEG ratio of 1.17 and a beta of 0.60. The stock has a 50-day moving average of $83.14 and a 200 day moving average of $75.67. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period last year, the company earned $1.69 earnings per share. Solventum’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Sell-side analysts anticipate that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the subject of several recent research reports. Wells Fargo & Company reduced their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Mizuho set a $113.00 price target on Solventum in a research report on Thursday, August 6th. UBS Group lifted their price target on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wedbush boosted their price target on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Finally, Stifel Nicolaus upped their price objective on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Moderate Buy” and an average target price of $91.64.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.